Consider investing in companies leading the Artificial Intelligence (AI) automation wave for businesses. A massive, underserved market exists in providing easy-to-use AI tools to millions of small and medium-sized businesses (SMBs) seeking to improve efficiency. Actively look for publicly traded software companies that enable the type of automation used by private firms like Cost Plus Drugs. Pay special attention to innovators developing AI agents, which are AIs that can autonomously perform complex tasks and workflows. These technology enablers are well-positioned for growth as AI adoption becomes essential for businesses to compete.

Investment Theme: Artificial Intelligence (AI)

• The discussion highlights Artificial Intelligence (AI) as a major force for automating manual business processes.
• A key opportunity exists within small and medium-sized businesses (SMBs). There are millions of these companies that are under pressure to compete with larger corporations but often lack the resources or knowledge to implement AI on their own.
• This creates a large market for companies that can provide easy-to-use AI tools and services to help these SMBs automate and become more efficient.
• The concept of AI agents—AI systems that can autonomously perform tasks and automate workflows—is specifically mentioned as a key area of development and application.

Takeaways

• Investors should consider companies that are leaders in providing AI-powered automation tools, particularly those targeting the small and medium-sized business (SMB) market.
• Look for businesses that make AI implementation simple and accessible, as they are positioned to capture a large, underserved segment of the economy.
• The development of AI agents is a specific technological trend to watch. Companies at the forefront of creating and deploying these agents could see significant growth.

Cost Plus Drugs

• Mark Cuban's company, Cost Plus Drugs, was mentioned as a real-world example of how a business is using AI.
• The company employs a person whose sole job is to identify manual processes within the company and find ways to automate them using technology.
• This demonstrates a practical, high-return-on-investment application of AI that improves efficiency and competitiveness.

Takeaways

• Cost Plus Drugs is a private company and is not available for public investment on the stock market.
• The key insight for investors is to use its strategy as a model. The way Cost Plus Drugs is implementing automation highlights the real-world demand for AI tools.
• Investors can look for publicly traded companies that enable this type of automation for other businesses. These would be the software and service providers that sell the tools that companies like Cost Plus Drugs use to become more efficient.